Company / Revenue
Tandem Diabetes Care Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$1.0B
FY2025
5-year range
$362.3M / $1.0B
FY2021-FY2025
Trend
+7.9%
vs FY2024
Sector context
#102 of 156
Health Care
What the data says
At $1.0B, Tandem Diabetes Care's revenue ranks #102 of 156 in the Health Care sector. Revenue has increased for 8 consecutive years, from $73M in FY2017 to $1.0B in FY2025.
Based on SEC 10-K filings.
$1.0B in FY2025 with a 5-year CAGR of +40.7%.
Improved from $748M to $1.0B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +26.7%
- 5-Year CAGR
- +40.7%
- 10-Year CAGR
- -
Sector benchmark
#102 of 156 in Health CareTop 65% of 156This company $1.0B Sector average $19.0B
▼
-94.7% below sector average
Key checks
Key Insights
- Tandem Diabetes Care's revenue has grown for 8 consecutive years.
- 5-year CAGR of +40.7%, indicating consistent growth.
- In FY2025, revenue increased 7.9% year-over-year.
- Ranks #102 out of 156 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0B | +7.9% |
| FY2024 | $940.2M | +25.7% |
| FY2023 | $747.7M | +49.9% |
| FY2022 | $498.8M | +37.7% |
| FY2021 | $362.3M | +97.0% |
| FY2020 | $183.9M | +70.9% |
| FY2019 | $107.6M | +27.7% |
| FY2018 | $84.2M | +15.6% |
| FY2017 | $72.8M | -13.5% |
| FY2016 | $84.2M | +15.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026